GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lavipharm SA (FRA:BXA0) » Definitions » Accounts Payable

Lavipharm (FRA:BXA0) Accounts Payable : €11.60 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Lavipharm Accounts Payable?

Lavipharm's Accounts Payable for the quarter that ended in Jun. 2024 was €11.60 Mil.

Lavipharm's quarterly Accounts Payable declined from Jun. 2023 (€10.43 Mil) to Dec. 2023 (€9.96 Mil) but then increased from Dec. 2023 (€9.96 Mil) to Jun. 2024 (€11.60 Mil).

Lavipharm's annual Accounts Payable increased from Dec. 2021 (€6.36 Mil) to Dec. 2022 (€7.77 Mil) and increased from Dec. 2022 (€7.77 Mil) to Dec. 2023 (€9.96 Mil).


Lavipharm Accounts Payable Historical Data

The historical data trend for Lavipharm's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lavipharm Accounts Payable Chart

Lavipharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable
Get a 7-Day Free Trial 6.03 4.53 6.36 7.77 9.96

Lavipharm Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 7.65 7.77 10.43 9.96 11.60

Lavipharm Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


Lavipharm Accounts Payable Related Terms

Thank you for viewing the detailed overview of Lavipharm's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Lavipharm Business Description

Traded in Other Exchanges
Address
Agias Marinas Street, PO Box 59, Peania Attica, GRC, 19002
Lavipharm SA develops, manufactures, markets and distributes pharmaceutical, cosmetic and consumer health products in Greece and internationally. The company's product portfolio includes innovative, safe and effective therapeutic solutions that meet consumer' needs for health and wellbeing. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, General Medicine, Self- Treatment and Dermocosmetic care.

Lavipharm Headlines

No Headlines